Colorectal cancer(CRC)continues to be the third most frequently diagnosed cancer,and the second leading cause of cancer-related mortality.Several non-invasive biomarkers have emerged,but only a few have been incorpora...Colorectal cancer(CRC)continues to be the third most frequently diagnosed cancer,and the second leading cause of cancer-related mortality.Several non-invasive biomarkers have emerged,but only a few have been incorporated into clinical practice due to the lack of sensitivity.1 Research on the epigenome has unveiled potential clinical applications for diagnosis and therapy response.2,3 Particularly,recent evidence suggests a novel role of RNA methylation in the development of CRC,4 revealing an overall RNA m6A hypomethylation.5 However,our understanding of their contribution to CRC remains limited.展开更多
基金supported by the“Centro de Investigacion Biomédica en Red Fisiopatología de la Obesidad y Nutricion”,which is an initiative of the“Instituto de Salud Carlos III”(ISCIII)of Spain,financed by the European Regional Development Fund under“A way to make Europe"/"Investing in your future”(CB06/03),a grant from ISCIII(No.PI18/01399,PI21/00633)UMA-FEDERJA-085,from Programa Operativo FEDER 2014–2020 of the Consejería de Economía y Conocimiento de la Junta de Andalucía+4 种基金a grant from the Consejeria Universidad,Investigacion e Innovacion Junta de Andalucia(No.PY20-01270,PI0293-2019)H.B.was supported by a predoctoral fellowship“Plan Propio IBIMA 2020 A.1 Contratos predoctorales”(No.predoc20_002)by a“Sara Borrell”postdoctoral contract(No.CD22/00053)from the Instituto de Salud Carlos III—Madrid(Spain),“Financiado por la Unión Europea—NextGenerationEU”,and the plan Recuperación,Transformación y Resiliencia.L.A.G.-F.was supported by a“Sara Borrell”postdoctoral contract(No.CD21/000131)from the Instituto de Salud Carlos III—Madrid(Spain)G.M.M.-N.was supported by a postdoctoral contract from the University of Malaga(No.UMA20-FEDERJA-092)M.M.G.was the recipient of the Nicolas Monardes Programme from the“Servicio Andaluz de Salud,Junta de Andalucia”,Spain(No.RC-0001-2018,C-0029-2014).
文摘Colorectal cancer(CRC)continues to be the third most frequently diagnosed cancer,and the second leading cause of cancer-related mortality.Several non-invasive biomarkers have emerged,but only a few have been incorporated into clinical practice due to the lack of sensitivity.1 Research on the epigenome has unveiled potential clinical applications for diagnosis and therapy response.2,3 Particularly,recent evidence suggests a novel role of RNA methylation in the development of CRC,4 revealing an overall RNA m6A hypomethylation.5 However,our understanding of their contribution to CRC remains limited.
